Free Trial

Actuate Therapeutics (ACTU) 10K Form and Latest SEC Filings 2026

Actuate Therapeutics logo
$3.07 +0.12 (+4.07%)
Closing price 04:00 PM Eastern
Extended Trading
$3.08 +0.01 (+0.16%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Actuate Therapeutics SEC Filings & Recent Activity

Actuate Therapeutics (NASDAQ:ACTU) has submitted 101+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form SCHEDULE 13G/A submitted on April 22, 2026.

Form 4
ACTUATE THERAPEUTICS, INC. Reports Ownership Change on Apr. 1, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-Q
Actuate Therapeutics Files Quarterly Report on Nov. 13, 2025

The 10-Q contains Actuate Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Actuate Therapeutics SEC Filing History

Browse Actuate Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/22/2026 2:24 PM
Actuate Therapeutics (1652935) Subject
Voss Capital, LP (1730145) Filed by
Form SCHEDULE 13G/A
04/09/2026 3:04 PM
Actuate Therapeutics (1652935) Filer
Form ARS
04/06/2026 3:06 PM
Actuate Therapeutics (1652935) Filer
Form DEFA14A
04/01/2026 4:19 PM
Actuate Therapeutics (1652935) Issuer
LYTLE PAUL J (1244110) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2026 4:19 PM
Actuate Therapeutics (1652935) Issuer
Mazar Andrew Paul (1727393) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2026 4:19 PM
Actuate Therapeutics (1652935) Issuer
SCHMITT DANIEL M (1318470) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 5:10 PM
Actuate Therapeutics (1652935) Issuer
SCHMITT DANIEL M (1318470) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 3:00 PM
Actuate Therapeutics (1652935) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2026 11:45 AM
Actuate Therapeutics (1652935) Issuer
Kairos Venture Partners II, L.P. (1696711) Reporting
THOMSON TODD S (1225707) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 11:25 AM
Actuate Therapeutics (1652935) Subject
Voss Capital, LP (1730145) Filed by
Form SCHEDULE 13G
12/11/2025 3:22 PM
Actuate Therapeutics (1652935) Subject
Kairos Venture Partners II, L.P. (1696711) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/28/2025 4:19 PM
Actuate Therapeutics (1652935) Filer
Form 424B5
11/28/2025 4:21 PM
Actuate Therapeutics (1652935) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/21/2025 3:30 PM
Actuate Therapeutics (1652935) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 3:00 PM
Actuate Therapeutics (1652935) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
09/10/2025 4:05 PM
Actuate Therapeutics (1652935) Filer
Form 424B5
09/10/2025 4:11 PM
Actuate Therapeutics (1652935) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/08/2025 11:15 PM
Actuate Therapeutics (1652935) Filer
Form EFFECT
08/04/2025 11:15 PM
Actuate Therapeutics (1652935) Filer
Form EFFECT
07/25/2025 3:00 PM
Actuate Therapeutics (1652935) Filer
Form S-1
Registration statement under Securities Act of 1933  
07/07/2025 3:37 PM
Actuate Therapeutics (1652935) Filer
Form D
Notice of Exempt Offering of Securities 
06/30/2025 12:01 PM
Actuate Therapeutics (1652935) Issuer
BIOS Actuate Co-Invest I, LP (1771378) Reporting
BIOS Actuate Co-Invest II, LP (1825398) Reporting
Bios Actuate Co-Invest III, LP (1956704) Reporting
BIOS Advisors GP, LLC (1813844) Reporting
BIOS Capital Management, LP (1813845) Reporting
BIOS Equity Partners III, LP (1831976) Reporting
BIOS Fund III NT, LP (1791910) Reporting
BIOS Fund III QP, LP (1791916) Reporting
BIOS Fund III, LP (1791917) Reporting
Fletcher Aaron G.L. (1789490) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2025 12:02 PM
Actuate Therapeutics (1652935) Issuer
Bios Equity Partners II, LP (1813313) Reporting
Bios Equity Partners, LP (1813314) Reporting
BIOS Fund I QP, LP (1700297) Reporting
BIOS Fund I, LP (1697316) Reporting
BIOS Fund II NT, LP (1728851) Reporting
BIOS Fund II QP, LP (1716869) Reporting
BIOS Fund II, LP (1714576) Reporting
Cavu Advisors, LLC (1813310) Reporting
Cavu Management, LP (1813270) Reporting
Kreis Leslie W. (1813316) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2025 12:03 PM
Actuate Therapeutics (1652935) Issuer
Bios 2024 Co-Invest, LP (2028708) Reporting
Bios Clinical Opportunity Fund, LP (1988639) Reporting
Bios Equity COF, LP (2000747) Reporting
BP Directors, LP (1813311) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2025 11:08 AM
Actuate Therapeutics (1652935) Subject
BIOS Fund I, LP (1697316) Filed by
Form SCHEDULE 13D/A
06/26/2025 7:11 AM
Actuate Therapeutics (1652935) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2025 1:57 PM
Actuate Therapeutics (1652935) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/02/2025 6:40 AM
Actuate Therapeutics (1652935) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/27/2025 3:15 PM
Actuate Therapeutics (1652935) Subject
BIOS Fund I, LP (1697316) Filed by
Form SCHEDULE 13D/A
05/23/2025 3:37 PM
Actuate Therapeutics (1652935) Issuer
THOMSON TODD S (1225707) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:05 PM
Actuate Therapeutics (1652935) Issuer
RONNEBERG AMY L (1380292) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:05 PM
Actuate Therapeutics (1652935) Issuer
Keyes Jason A (1678152) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:05 PM
Actuate Therapeutics (1652935) Issuer
Fletcher Aaron G.L. (1789490) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:05 PM
Actuate Therapeutics (1652935) Issuer
Zabrowski Dan (1940818) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:05 PM
Actuate Therapeutics (1652935) Issuer
Sawhney Roger (1858748) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2025 7:09 AM
Actuate Therapeutics (1652935) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Actuate Therapeutics SEC Filings - Frequently Asked Questions

Actuate Therapeutics (ACTU) has submitted 101+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Actuate Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form SCHEDULE 13G/A submitted on April 22, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ACTU) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners